Novel glutamatergic modulators for the treatment of mood disorders: current status
The efficacy of standard antidepressants is limited for many patients with mood disorders
such as major depressive disorder (MDD) and bipolar depression, underscoring the urgent …
such as major depressive disorder (MDD) and bipolar depression, underscoring the urgent …
[HTML][HTML] Development of allosteric modulators of GPCRs for treatment of CNS disorders
HH Nickols, PJ Conn - Neurobiology of disease, 2014 - Elsevier
The discovery of allosteric modulators of G protein-coupled receptors (GPCRs) provides a
promising new strategy with potential for developing novel treatments for a variety of central …
promising new strategy with potential for developing novel treatments for a variety of central …
Ketamine and the neurobiology of depression: Toward next-generation rapid-acting antidepressant treatments
JH Krystal, AP Kaye, S Jefferson… - Proceedings of the …, 2023 - National Acad Sciences
Ketamine has emerged as a transformative and mechanistically novel pharmacotherapy for
depression. Its rapid onset of action, efficacy for treatment-resistant symptoms, and …
depression. Its rapid onset of action, efficacy for treatment-resistant symptoms, and …
Practical strategies and concepts in GPCR allosteric modulator discovery: recent advances with metabotropic glutamate receptors
CW Lindsley, KA Emmitte, CR Hopkins… - Chemical …, 2016 - ACS Publications
Allosteric modulation of GPCRs has initiated a new era of basic and translational discovery,
filled with therapeutic promise yet fraught with caveats. Allosteric ligands stabilize unique …
filled with therapeutic promise yet fraught with caveats. Allosteric ligands stabilize unique …
Glutamate modulators as potential therapeutic drugs in schizophrenia and affective disorders
Severe psychiatric disorders such as schizophrenia are related to cognitive and negative
symptoms, which often are resistant to current treatment approaches. The glutamatergic …
symptoms, which often are resistant to current treatment approaches. The glutamatergic …
Targeting mGluR2/3 for treatment of neurodegenerative and neuropsychiatric diseases
SH Li, KS Abd-Elrahman, SSG Ferguson - Pharmacology & therapeutics, 2022 - Elsevier
Glutamate is the primary excitatory neurotransmitter in the brain and plays critical roles in all
aspects of neuronal function. Disruption of normal glutamate transmission has been …
aspects of neuronal function. Disruption of normal glutamate transmission has been …
Sex differences in glutamate receptor gene expression in major depression and suicide
AL Gray, TM Hyde, A Deep-Soboslay… - Molecular …, 2015 - nature.com
Accumulating data indicate that the glutamate system is disrupted in major depressive
disorder (MDD), and recent clinical research suggests that ketamine, an antagonist of the N …
disorder (MDD), and recent clinical research suggests that ketamine, an antagonist of the N …
Targeting metabotropic glutamate receptors for the treatment of depression and other stress-related disorders
The discovery of robust antidepressant effects of ketamine in refractory patients has led to
increasing focus on agents targeting glutamatergic signaling as potential novel …
increasing focus on agents targeting glutamatergic signaling as potential novel …
International union of basic and clinical pharmacology. CXI. Pharmacology, signaling, and physiology of metabotropic glutamate receptors
KJ Gregory, C Goudet - Pharmacological reviews, 2021 - ASPET
Metabotropic glutamate (mGlu) receptors respond to glutamate, the major excitatory
neurotransmitter in the mammalian brain, mediating a modulatory role that is critical for …
neurotransmitter in the mammalian brain, mediating a modulatory role that is critical for …
Faster, better, stronger: towards new antidepressant therapeutic strategies
Major depression is a highly prevalent disorder and is predicted to be the second leading
cause of disease burden by 2020. Although many antidepressant drugs are currently …
cause of disease burden by 2020. Although many antidepressant drugs are currently …